Emergent BioSolutions Inc. (EBS)
| Previous Close | 3.3000 |
| Open | 3.4500 |
| Bid | 3.5900 x 1100 |
| Ask | 3.6000 x 1200 |
| Day's Range | 3.3600 - 4.0200 |
| 52 Week Range | 1.4200 - 10.8800 |
| Volume | |
| Avg. Volume | 5,480,596 |
| Market Cap | 192.274M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Emergent BioSolutions Reports First Quarter 2024 Financial Results
First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products,” said Joe Papa, President and CEO at Emergent. “We also took significa
- GlobeNewswire
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business goals, strategic priorities and new operational planOverall efforts expected to deliver annual cost savings of approximately $80 million GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates
- GlobeNewswire
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an emergency GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college stude
